How to Read a Kratom Microbiology COA: Salmonella, E. coli, Yeast, Mold and CFU Explained

August 30, 2026

Last reviewed: September 1, 2026. Educational content for adults 21+. This is not medical or legal advice. Kiody does not sell concentrated 7-OH products.

The short answer

A useful kratom microbiology certificate of analysis should tell you more than whether every row says “pass.” It should identify the tested lot, product form, sample amount, analytical method, reporting units, result and approved specification.

The first distinction to make is between two kinds of tests:

Pathogen detection tests, commonly reported as “detected” or “not detected” in a defined analytical portion, such as 25 grams.
Enumeration tests, reported as an estimated number of viable organisms in a unit of material, commonly colony-forming units per gram, or CFU/g.

Those answers are not interchangeable. “Salmonella: not detected in 25 g” describes the outcome for the tested analytical portion under the stated method. “Aerobic plate count: 2,400 CFU/g” estimates a count. Neither line, by itself, proves that every package from the lot is contamination-free.

A seven-step review is a good starting point:

Match the COA to the product and lot.
Identify whether each row is a pathogen or an indicator/count test.
Confirm the sample amount and reporting unit.
Find the actual result—not merely a green “pass” icon.
Find the specification and who established it.
Check the method, laboratory, dates and any qualifiers.
Review the microbiology panel together with sampling, storage, manufacturing and release records.

Why microbiology belongs in kratom quality review

Kratom leaf is an agricultural material. Harvesting, drying, grinding, handling, storage, blending and packaging create multiple points where microorganisms may be introduced, redistributed or allowed to grow if conditions permit. A clean-looking powder is not microbiological evidence, and a strain or color name does not predict microbial quality.

FDA has documented the issue in actual kratom commerce. In 2018, FDA and CDC investigated a multistate outbreak of Salmonella infections linked to products reported to contain kratom. FDA later used its mandatory recall authority for certain kratom products during that response. FDA 2018 outbreak update and FDA mandatory recall announcement.

The concern is not only historical. FDA published a recall on October 31, 2025 for multiple lots and package sizes of Monarch Premium kratom powder after a retail sample collected and analyzed by the Florida Department of Agriculture and Consumer Services revealed Salmonella in finished product. The recalled forms included Bali Gold, Red Bali, Green Maeng Da and White Elephant powders. That episode is a useful reminder that a variety name is not a safety control and that testing must remain connected to the exact lot. FDA recall notice.

FDA’s current kratom page also states that the agency has warned the public about products contaminated with Salmonella and concerning levels of heavy metals. That agency position is separate from this guide’s narrower purpose: teaching readers what a microbiology COA does and does not show. FDA and Kratom.

The quality-system baseline

FDA states that kratom has not been lawfully marketed in the United States as a conventional food or dietary supplement. Referring to dietary-supplement current good manufacturing practice requirements here does not imply FDA approval of kratom or a Kiody product.

Part 111 nevertheless supplies a useful quality-system framework for products represented as dietary supplements. Under 21 CFR §111.70, a manufacturer must establish limits on types of contamination that may adulterate or lead to adulteration of components, in-process material and finished batches. The regulation does not publish one universal microbiology table for every botanical and every product form. The responsible firm must establish scientifically justified specifications appropriate to its material, process and intended product.

Part 111 also requires, as applicable:

Appropriate, scientifically valid tests or examinations under 21 CFR §111.75;
Laboratory operations using appropriate methods and written procedures under 21 CFR Part 111, Subpart J;
Microbiological or other testing as necessary to prevent contaminated components from being used under 21 CFR Part 111, Subpart K;
Controls for personnel, facilities, equipment, sanitation, water and production; and
Quality-control review and release or rejection decisions.

The word specification matters. A laboratory result answers what the method found in the sample. A specification states the approved acceptance criterion. A regulation states a legal requirement. A laboratory reporting limit states what the method can reliably report. These four things may interact, but they are not synonyms.

The panel at a glance

Microbiology panels vary. A common botanical panel may contain some combination of the following:

COA row	Typical result type	What it generally addresses
Salmonella spp.	Detected/not detected in a defined amount	Targeted pathogen detection
Shiga toxin-producing E. coli or E. coli O157:H7	Detected/not detected in a defined amount	Targeted pathogenic E. coli detection
Generic E. coli	CFU/g, MPN/g or presence/absence	Sanitary indicator, depending on method and specification
Total coliforms	CFU/g or MPN/g	General sanitary indicator in appropriate applications
Aerobic plate count	CFU/g	Broad estimate of culturable aerobic organisms under stated conditions
Total yeast and mold	CFU/g	Estimate of culturable yeasts and molds under stated conditions
Staphylococcus aureus	CFU/g or detection	Organism-specific enumeration or detection, depending on method
Listeria monocytogenes	Detected/not detected in a defined amount	Targeted pathogen detection when relevant to the product and risk assessment

The panel name alone does not establish what was done. “E. coli” could mean enumeration of generic E. coli, a targeted pathogen screen or a combined coliform/E. coli method. The scientific name, method reference, sample amount and reporting format should resolve the ambiguity.

Salmonella: what “not detected in 25 g” means

FDA’s Bacteriological Analytical Manual, or BAM, presents the agency’s preferred laboratory procedures for microbiological analyses of foods and cosmetics. FDA updated the BAM main page on August 6, 2026, and the current Salmonella page directs laboratories to BAM Chapter 5 and its rapid-method appendix. FDA BAM and BAM Chapter 5.

A Salmonella analysis commonly begins with a defined analytical portion placed into a pre-enrichment medium. The procedure then uses enrichment, screening and confirmation steps designed to recover and identify the target organism. The exact workflow depends on the approved method.

When a COA says:

Salmonella: Not detected / 25 g

it generally means the laboratory did not detect Salmonella in the 25-gram analytical portion using the stated method and test conditions. It does not literally mean:

Zero Salmonella cells exist anywhere in the production lot;
Every retail pouch or capsule bottle was tested;
The rest of the microbiology panel passed;
The package cannot become contaminated after sampling;
Storage conditions cannot affect later quality; or
A different analytical portion would be guaranteed to produce the same result.

Microbial contamination can be unevenly distributed. A result therefore depends on the sampling plan as well as the analytical method. A 25-gram portion drawn from a representative composite of a defined finished lot provides different evidence from 25 grams scooped from one convenient container with no documented selection plan.

“Absent,” “negative” and “not detected”

These terms may be used differently by different laboratories. “Not detected” is usually the clearest phrasing because it ties the conclusion to the method and analytical amount. “Absent” can be misread as an absolute statement about the entire lot. “Negative” should identify the target, sample amount and method rather than standing alone.

Screening versus confirmation

Rapid molecular methods can produce a presumptive screening result faster than a traditional cultural workflow. The COA or laboratory record should make clear whether the reported answer is presumptive, confirmed or final under the method. A PCR signal is not automatically equivalent to a recovered, culturally confirmed viable isolate; interpretation depends on the validated method, enrichment and confirmation scheme.

A buyer should not be expected to reconstruct an entire laboratory method from a one-page COA, but the report should identify the method well enough that a qualified reviewer can obtain and evaluate it.

E. coli: three different questions hiding under one name

An E. coli row needs careful reading because it may address different organisms and different purposes.

Generic E. coli

Generic E. coli can be used as an indicator in appropriate applications. A result may be enumerated as CFU/g or estimated through a most probable number procedure as MPN/g. FDA’s BAM Chapter 4 explains that coliforms, fecal coliforms and E. coli serve as indicators in different applications. BAM Chapter 4.

An indicator result does not identify every possible pathogen. A low generic E. coli count cannot replace a targeted Salmonella analysis, and a Salmonella result cannot replace an indicator count when the specification requires one.

E. coli O157:H7

E. coli O157:H7 is a specific pathogenic type. A targeted test is normally presented as detection in a defined analytical amount, not as the same generic E. coli count used for sanitation indicators.

Non-O157 Shiga toxin-producing E. coli

Other Shiga toxin-producing E. coli, often abbreviated STEC, require their own appropriate detection and confirmation approach. FDA maintains a separate BAM Chapter 4A for diarrheagenic E. coli. BAM Chapter 4A.

A COA row that merely says “E. coli: pass” leaves too much unanswered. It should identify whether the method addressed generic E. coli, O157:H7, specified STEC targets or another defined group.

Aerobic plate count: a broad count, not a pathogen test

Aerobic plate count may also appear as APC, aerobic microbial count, standard plate count or a method-specific variation. FDA’s current BAM Chapter 3 is the January 2026 edition. BAM Chapter 3.

APC estimates colonies produced by organisms able to grow under the method’s media, atmosphere, incubation time and temperature. It does not count every living organism in the powder, and it does not identify each colony to species.

An APC result can help with:

Lot release against an established limit;
Supplier and process trending;
Investigation of sanitation, drying or storage changes;
Comparison of untreated and validated treated material; and
Detection of unusual shifts even when a lot still meets its limit.

An APC result cannot establish that Salmonella, pathogenic E. coli or another specific pathogen is absent. A lot may have a relatively modest APC and still fail a targeted pathogen test. Conversely, an agricultural material can have a measurable APC without that count alone proving the presence of a pathogen.

Yeast and mold: count the viable colonies, then interpret carefully

Yeast and mold testing typically estimates culturable fungi under specified conditions. FDA’s BAM Chapter 18 describes analytical procedures for yeasts and molds and discusses their diverse environmental requirements. BAM Chapter 18.

Three distinctions are essential:

A yeast and mold count is not a mycotoxin assay.
A low count today does not prove that poor storage cannot support later growth.
A visible foreign particle investigation is not the same as a viable mold count.

Mycotoxins are chemical substances produced by certain molds under certain conditions. Testing for culturable yeast and mold does not automatically measure aflatoxins, ochratoxin A or other specific mycotoxins. A product specification should say which question the test is meant to answer. Kiody’s mycotoxin COA guide explains the separate chemical analysis.

Moisture content, water activity, packaging, oxygen exposure, temperature and storage time can influence stability and microbial behavior. A COA should therefore be read as one part of the lot record, not as permission to disregard storage controls.

CFU/g, MPN/g and logarithms

CFU per gram

CFU/g means colony-forming units per gram. It is an estimate based on colonies produced under the method conditions. A colony may arise from one viable cell or a cluster of cells, which is one reason “CFU” is more accurate than simply saying “bacteria per gram.”

Examples:

10 CFU/g means an estimated ten colony-forming units per gram.
1,000 CFU/g can be written as 1.0 × 10³ CFU/g.
25,000 CFU/g can be written as 2.5 × 10⁴ CFU/g.

MPN per gram

MPN/g means most probable number per gram. It is a statistical estimate derived from patterns of positive and negative tubes or wells across dilutions. FDA provides tables and calculation guidance in BAM Appendix 2. BAM Appendix 2.

CFU/g and MPN/g should not be casually substituted for one another. If a specification is written in one format and the result in another, a qualified reviewer should confirm that the method and decision rule support the comparison.

Log values

Microbial counts are sometimes displayed on a base-10 logarithmic scale:

10 CFU/g = 1 log10 CFU/g
100 CFU/g = 2 log10 CFU/g
1,000 CFU/g = 3 log10 CFU/g
10,000 CFU/g = 4 log10 CFU/g

A change from 2 log to 3 log is a tenfold change, not a one-percent or one-unit increase in the ordinary sense.

A worked conversion

A COA reports aerobic plate count as 3.2 × 10³ CFU/g.

Move the decimal three places:

3.2 × 1,000 = 3,200 CFU/g.

If the approved maximum is 10,000 CFU/g, the numerical result is below that specification. It should not be described as “sterile,” “zero bacteria” or a pathogen-negative result.

ND, less-than signs, estimated counts and TNTC

Not detected, or ND

For a pathogen method, ND should be linked to a defined sample amount: for example, “not detected in 25 g.” For an enumeration method, ND or a less-than result should be linked to the reporting limit.

Less than the reporting limit

Suppose a yeast and mold result is <10 CFU/g. That does not necessarily mean zero. It means the result fell below the method’s stated reporting level under the tested conditions.

If the approved maximum were 100 CFU/g, a properly supported <10 CFU/g result would be below the numerical limit. But the reviewer should still verify the method, dilution and reporting limit.

Estimated result

A plate may have colonies outside the method’s preferred countable range. A laboratory may report an estimated count with a qualifier. Estimated does not automatically mean invalid, but the qualification affects how confidently the result can be used, particularly near a specification.

Too numerous to count, or TNTC

TNTC means colony growth exceeded the countable range on the examined plate or dilution. It is not a numerical result and should not be converted into “pass.” The laboratory may need to examine an appropriate additional dilution according to its procedure. The final report should explain how the result was resolved.

Zero on one plate

“0 colonies observed” on a particular plate is not the same as an unlimited proof of absence. The tested mass, dilution, plated volume and method reporting limit still control the interpretation.

The sample amount is part of the result

Compare these three lines:

Salmonella: not detected in 25 g
Salmonella: not detected in 10 g
Salmonella: not detected

The first two do not present identical evidence because the analytical amounts differ. The third is incomplete unless the amount can be found elsewhere on the report or method.

For count methods, sample preparation and dilution also matter. BAM Chapter 1 addresses food sampling and preparation of sample homogenates. A common laboratory preparation uses a defined sample-to-diluent relationship before serial dilution and plating, but the exact method must be followed rather than assumed. BAM Chapter 1.

The COA does not need to print every pipetting step. It should, however, let a qualified reviewer identify:

The submitted sample;
Analytical amount;
Method and version;
Result and unit;
Reporting limit or qualifier when relevant; and
Specification used for the pass/fail decision.

Representative sampling matters as much as careful analysis

A laboratory can test the submitted material correctly and still produce evidence that poorly represents the lot if the sample was selected badly.

Useful sampling records address:

How the lot was defined;
Number and location of containers or units selected;
Random or stratified selection process;
Number and size of increments;
Whether increments were composited;
Tools and containers used;
Measures used to prevent cross-contamination;
Sample identification, sealing and chain of custody;
Transport and storage conditions; and
Quantity retained for possible investigation.

Microorganisms can occur in clusters. Increasing analytical sophistication does not fix a convenience sample drawn only from the easiest-to-reach top layer of one bag.

This is why “five pathogens tested” is not automatically stronger evidence than one appropriate method performed on a representative sample. Test scope and sampling quality must be considered together.

Method suitability for the product matrix

A method that works for plain leaf powder may not perform identically with a concentrated extract, flavored liquid, gummy, capsule shell or multi-ingredient blend. The product matrix can affect recovery, dilution, inhibition, background flora and interpretation.

Questions for method review include:

Is the method intended or validated for this matrix or a scientifically appropriate comparable matrix?
Can the laboratory recover the target organism at relevant levels from the product?
Does the material inhibit PCR, growth or confirmation reactions?
Are positive, negative and matrix controls appropriate?
Does the laboratory use the correct sample amount?
Are enrichment, incubation and confirmation conditions controlled?
Is the reporting limit suitable for the specification?
Were deviations documented and assessed?

Accreditation can support confidence in laboratory competence, but an accreditation logo does not prove that every method, matrix, sample or calculation on a COA was appropriate. The scope of accreditation and the actual test method matter.

There is no honest one-number “microbial purity score”

Microbiology results answer different questions. Combining them into a single score can hide a critical failure.

Consider a panel with:

APC below limit;
Yeast and mold below limit;
Generic E. coli below limit; and
Salmonella detected.

Three favorable rows cannot average away the detected pathogen. Each specification must be evaluated according to its own decision rule.

The reverse is also important. An APC above the approved maximum cannot be relabeled a pathogen failure unless a pathogen was actually detected. It is an out-of-specification count that requires control, investigation and disposition based on the established quality system.

No universal kratom microbiology limit should be invented

It is tempting to copy a microbial limit table from another botanical, food, pharmacopeial category, trade program or jurisdiction and present it as the single federal kratom standard. That would be misleading.

The responsible review should identify:

The product’s approved internal specification;
The scientific and regulatory basis for that specification;
The applicable jurisdiction and product category;
The analytical method and reporting capability;
The actual result; and
The predetermined decision rule.

Part 111 requires firms within its scope to establish relevant contamination limits, but it does not supply one kratom-specific numerical table. FDA’s BAM provides methods, not a universal finished-kratom acceptance specification.

A COA that cites “FDA limits” without naming an actual statute, regulation, guidance or specification source deserves follow-up.

Product-form differences

Botanical leaf powder

Powder can contain naturally occurring environmental organisms and can be exposed during drying, milling, blending and packaging. The sampling plan should account for large lots and possible uneven distribution.

Pure-leaf capsules

Kiody describes its capsules as approximately 500 mg of pure leaf powder per capsule. A capsule microbiology review should match the finished capsule lot, not merely an unrelated bulk-powder COA. Capsule shells, filling equipment, handling and packaging are part of the finished-product history.

Extract powders

Extraction and drying may change microbial load, but the word “extract” does not prove a validated microbial reduction. Carriers and post-process handling can introduce separate risks.

Liquids and beverages

Water activity, pH, ingredients, preservatives, container closure and storage conditions affect the microbiological control strategy. A dry-powder method should not be assumed suitable for a liquid matrix.

Gummies and multi-ingredient products

Added sugars, flavors, acids, water, gelatin or pectin and other components change the matrix. Every ingredient and post-process exposure must be considered.

Enhanced products and concentrated 7-OH

A passing microbiology panel does not establish alkaloid composition or legal status. Concentrated 7-OH requires separate composition and legal review. Kiody does not sell concentrated 7-OH.

Five worked COA reviews

Scenario 1: a clear pathogen result

Report: Salmonella spp., not detected in 25 g
Specification: Not detected in 25 g
Method: Identified validated method
Lot match: Exact finished-product lot

Review: The reported analytical portion meets the stated specification under the identified method. Confirm representative sampling, laboratory status, dates and final quality release. Describe the result as “not detected in the tested 25-gram portion,” not “the entire lot contains zero Salmonella.”

Scenario 2: a green pass with no result

Report: Salmonella — PASS
Specification: Blank
Sample amount: Blank
Method: “Internal”

Review: Insufficient for independent interpretation. Request the actual result language, analytical amount, method identifier, specification and basis for the decision. A green icon is not analytical data.

Scenario 3: an aerobic count below limit

Result: 4.6 × 10³ CFU/g
Specification: ≤1.0 × 10⁴ CFU/g

Convert both values:

Result = 4,600 CFU/g
Maximum = 10,000 CFU/g

Review: The numerical result is below the stated maximum. It is not a Salmonella result and does not prove sterility. Compare it with prior lots for unusual trends and confirm that the method and matrix are appropriate.

Scenario 4: yeast and mold below reporting limit

Result: <10 CFU/g
Specification: ≤100 CFU/g
Reporting limit: 10 CFU/g

Review: The result is below the method’s stated reporting level and below the approved maximum. It should be recorded as “<10 CFU/g,” not rewritten as zero. Review packaging, moisture and storage evidence separately.

Scenario 5: mixed results cannot be averaged

APC: 1,200 CFU/g, passes
Yeast and mold: 30 CFU/g, passes
Generic E. coli: <10 CFU/g, passes
Salmonella: Detected in 25 g, fails

Review: The lot fails the Salmonella specification. The favorable counts do not offset or average away the pathogen result. Control the lot, investigate, assess related material and make a documented disposition. Do not release it because “three of four tests passed.”

Twenty microbiology COA warning signs

The lot number on the COA does not match the package.
The report says only “pass” without actual results.
A pathogen row omits the tested analytical amount.
Results appear in CFU/g but specifications appear in a different, unexplained unit.
“E. coli” is listed without identifying generic or pathogenic targets.
A method is listed as “USP,” “FDA” or “AOAC” with no procedure identifier.
The laboratory report has no issue date or sample-receipt date.
Testing predates manufacture of the stated finished lot.
A bulk-material COA is presented as finished-product testing without explanation.
The same COA is used for powder, capsules, liquid and gummies.
The report claims “sterile” based on routine microbial limits testing.
A <10 CFU/g result is rewritten as 0 CFU/g.
TNTC is marked as passing.
A presumptive screen is presented as a confirmed final result without context.
A result near the limit has been rounded without a stated rule.
The COA provides no specification or source for a claimed “FDA limit.”
A detected pathogen is ignored because total count is low.
Retesting replaces the original failure with no investigation trail.
The sample is described only as “kratom” with no form, batch or container information.
The laboratory, brand and supplier cannot explain how the sample represented the lot.

One warning sign may have a reasonable explanation. Several together indicate that the COA is not enough to support release or a public quality claim.

A proposed Kiody microbiology review record

For editorial and quality review, capture at least these fields:

Product name;
Product form;
Finished-product lot;
Component or source lot, if relevant;
Batch size;
Manufacture or packaging date;
Sampling date;
Sampler and organization;
Sampling plan identifier;
Number of increments and containers sampled;
Composite or individual-sample status;
Chain-of-custody identifier;
Laboratory name;
Laboratory accreditation and relevant scope;
Laboratory accession number;
Sample receipt date and condition;
Test start and completion dates;
Analyte or organism exactly as reported;
Pathogen-detection or enumeration classification;
Method and version;
Matrix suitability or validation reference;
Analytical portion;
Result;
Unit;
Reporting limit or detection capability;
Specification;
Specification source and version;
Qualifiers or deviations;
Initial pass/fail decision;
Reviewer and review date;
Investigation number, if applicable;
Final disposition;
Related-lot assessment;
COA version and approval history.

This record is not a substitute for the laboratory package or batch record. It is a structured index that helps reviewers detect missing links.

Responsible-use and consumer questions

A customer does not need to be a microbiologist to ask sensible questions:

Does the package lot match the COA?
Was the finished product tested, or only a raw component?
Does the Salmonella row say how much was tested?
Are the results and specifications both visible?
Is the laboratory identified?
Are the testing dates plausible for the lot?
Does the company provide storage instructions?
Is there a recall or contact process tied to the lot?

Testing cannot make personal use medically safe or appropriate. Adults should keep botanical products secured from children and animals, follow product storage directions, avoid using damaged or contaminated packaging, and consult an appropriate professional for medical or medication questions. A COA is product-quality evidence, not medical advice.

Current 7-OH and derivative context

Microbiological compliance and controlled-substance status are separate reviews.

As of September 1, 2026, DEA’s proposal to place 7-OH above a specified threshold in Schedule I remains a proposal, and the comment period has been extended through September 10, 2026. The proposed thresholds and denominators should not be presented as final federal law. DEA comment-period extension.

A separate DEA temporary order placed mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I effective August 26, 2026. A clean microbiology COA does not make a product containing those controlled compounds lawful. DEA temporary scheduling order.

Kiody is 21+ and does not sell concentrated 7-OH. Review the nationwide botanical kratom law tracker and nationwide 7-OH law tracker for jurisdiction-specific information.

Frequently asked questions

1. What does CFU/g mean on a kratom COA?

It means colony-forming units per gram. It estimates colonies produced by viable organisms under the method’s stated conditions. It is not a literal count of every microbial cell in the product.

2. Does “Salmonella not detected in 25 g” mean the whole lot is Salmonella-free?

It means Salmonella was not detected in the tested 25-gram analytical portion under the method. The strength of the lot conclusion also depends on representative sampling, method performance and process controls.

3. Is “not detected” the same as zero?

No. It means the target was not detected at the method’s capability in the tested portion. It should not be converted into an unlimited claim of absolute zero.

4. Why does the sample amount matter?

A presence/absence result is defined partly by the quantity examined. “Not detected in 25 g” and “not detected in 10 g” do not describe the same analytical amount.

5. What is the difference between generic E. coli and pathogenic E. coli?

Generic E. coli may be used as a sanitary indicator. Pathogenic groups such as O157:H7 or other STEC are specific hazards requiring appropriate targeted methods. The COA should identify which question was tested.

6. Does a low aerobic plate count prove pathogens are absent?

No. APC is a broad enumeration under defined growth conditions. It does not replace a targeted pathogen test.

7. Is yeast and mold testing the same as mycotoxin testing?

No. Yeast and mold counts estimate culturable fungi. Mycotoxin assays measure specified chemical toxins. One does not automatically answer the other.

8. What does <10 CFU/g mean?

It generally means the count was below a reporting level of 10 CFU/g under that method. It should remain reported as <10, not rewritten as zero.

9. What does TNTC mean?

Too numerous to count. The plate or dilution exceeded the method’s countable range. A laboratory should resolve and report it according to its procedure; TNTC should not be marked as a pass.

10. Can a product pass Salmonella and still fail microbiology?

Yes. It could exceed an approved aerobic, yeast and mold, indicator-organism or other applicable specification.

11. Can a product pass counts but fail Salmonella?

Yes. Counts and targeted pathogen detection answer different questions. A detected pathogen cannot be averaged away with favorable indicator counts.

12. Should pure-leaf capsules use the powder COA?

A raw-powder COA is relevant to the component but does not show every finished-capsule risk. Finished-product review should connect the powder lot, capsule shell, filling, packaging and finished lot.

13. Does heat treatment guarantee a safe finished lot?

No treatment should be assumed effective merely because heat was used. A responsible program needs a validated process, controlled operating parameters, protection against recontamination and finished-lot evidence appropriate to the risk.

14. Is an ISO/IEC 17025 laboratory automatically enough?

Accreditation is useful evidence, but reviewers should still confirm the relevant scope, method, matrix, sample identity, reporting limit and actual result.

15. Does a microbiology COA show the product is legal in every state?

No. Microbiology, alkaloid composition, labeling, age restrictions, seller registration and shipping law are separate reviews.

16. Does Kiody sell concentrated 7-OH?

No. Kiody is an adults-only, 21+ business and does not sell concentrated 7-OH.

17. Why can two samples from the same lot disagree?

Possible causes include uneven contamination, sampling differences, sample preparation, method variability or laboratory error. A discrepancy requires documented review; it should not be resolved by automatically choosing the better result.

18. What is the most important first check on a COA?

Verify that the product name, form and lot on the package match the tested sample. A technically excellent result from a different lot does not establish the quality of the package in hand.